← Back to Clinical Trials
Recruiting NCT06462430

NCT06462430 PTEN Hamartoma Tumor Syndrome Pediatric Patient Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06462430
Status Recruiting
Phase
Sponsor Yale University
Condition PTEN Hamartoma Tumor Syndrome
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2022-11-01
Primary Completion 2026-12-01

Eligibility & Interventions

Sex All sexes
Min Age 1 Year
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2022-11-01 with a primary completion date of 2026-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

PtenTurkiye.org' is a national ( Turkish), web-based registry for PTEN Hamartoma Tumour ( PHTS) syndrome established in 2022. It is designed to increase awareness, gather scientific knowledge by collaboration and increase data accessibility, collect high-quality data on the epidemiology, genetic background and natural history of PHTS especially for pediatric patients so that more accurate follow up guidelines can be recommended.

Eligibility Criteria

Inclusion Criteria: * Patients who have clinical findings of PHTS and have mutation in PTEN gene ( VUS included if show clinical findings) and agree to participate in the study Exclusion Criteria: * Patients who do not have clinical findings of PHTS and do not have mutation in PTEN gene and do not agree to participate in the study

Contact & Investigator

Central Contact

Hande Kaymakcalan Celebiler, MD

✉ hande.kaymakcalancelebiler@yale.edu

📞 +905323768107

Principal Investigator

Hande Kaymakcalan Celebiler, MD

PRINCIPAL INVESTIGATOR

Yale University

Frequently Asked Questions

Who can join the NCT06462430 clinical trial?

This trial is open to participants of all sexes, aged 1 Year or older, studying PTEN Hamartoma Tumor Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06462430 currently recruiting?

Yes, NCT06462430 is actively recruiting participants. Contact the research team at hande.kaymakcalancelebiler@yale.edu for enrollment information.

Where is the NCT06462430 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT06462430 clinical trial?

NCT06462430 is sponsored by Yale University. The principal investigator is Hande Kaymakcalan Celebiler, MD at Yale University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology